title: Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy.
abstract: Neuropeptide Y (NPY) is a potent vasoconstrictor peptide that is abundant in the brain and the peripheral sympathetic nervous system. In the present study we investigated possible changes in plasma immunoreactive (IR)-NPY concentrations and urinary IR-NPY excretion in patients with non-insulin dependent diabetes mellitus (NIDDM) and the relationship to diabetic complications, such as nephropathy and neuropathy. IR-NPY in plasma and urine was measured by radioimmunoassay in 69 patients with NIDDM. Plasma IR-NPY concentrations in patients with advanced nephropathy (creatinine clearance <30 ml/min) (100.5 +/- 10.3 pmol/l, n=9, mean +/- SEM) were higher than in the control subjects (55.0 +/- 6.8 pmol/l, n=15) (P<0.02). Urinary excretion of IR-NPY and fractional excretion of NPY were also increased in the patients with advanced nephropathy. Sephadex G-50 column chromatography of the urine extracts obtained from healthy subjects, diabetic patients with renal failure and non-diabetic patients with renal failure showed an immunoreactive peak eluting in the NPY position. On the other hand, neither plasma nor urinary IR-NPY was high in patients with retinopathy, or in patients with peripheral neuropathy. The present study has, for the first time, shown high plasma IR-NPY concentrations and urinary IR-NPY excretion in NIDDM patients with advanced nephropathy.
authors.affiliation: Second Department of Internal Medicine, Tohoku University School of Medicine, Miyagi, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Satoh
authors.forename: F
authors.initials: F
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: O
authors.initials: O
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Sone
authors.forename: K
authors.initials: K
authors.lastname: Totsune
authors.forename: T
authors.initials: T
authors.lastname: Yabe
authors.forename: M
authors.initials: M
authors.lastname: Ohneda
authors.forename: M
authors.initials: M
authors.lastname: Fukuda
authors.forename: K
authors.initials: K
authors.lastname: Sugimura
authors.forename: S
authors.initials: S
authors.lastname: Ogawa
authors.forename: H
authors.initials: H
authors.lastname: Nagakubo
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Mouri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000652:urine*; D003928:Diabetic Nephropathies / Q000097:blood* / Q000652:urine*; D003929:Diabetic Neuropathies / Q000097:blood / Q000652:urine; D003930:Diabetic Retinopathy / Q000097:blood / Q000652:urine; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood* / Q000652:urine*; D012016:Reference Values
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D009478:Neuropeptide Y